Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irpagratinib and ABSK043 in FGF19-Positive HCC
NCT06978933Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irpagratinib, lumipodlin in hepatocellular carcinoma (HCC), sponsored by Renji Hospital. Started Apr 2025; status: recruiting.
02
Drugs
irpagratiniblumipodlin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06978933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06978933.